A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men
Clinical trial NCT03422172 · COMPLETED
Trial details
- NCT number
- NCT03422172
- Sponsor
- ViiV Healthcare
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-10
- Primary completion
- 2020-04-20
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.